{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:23Z","timestamp":1789587023546,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s41669-017-0044-1","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T09:46:15Z","timestamp":1500371175000},"page":"109-123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends"],"prefix":"10.1007","volume":"2","author":[{"given":"Trevor Jozef","family":"Piatkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine Marie","family":"Traulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Holm-Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"44_CR1","volume-title":"Health at a Glance: Europe 2014","author":"OECD\/EU","year":"2014","unstructured":"OECD\/EU. Health at a Glance: Europe 2014. Paris: OECD Publishing; 2014."},{"key":"44_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1472-6963-10-153","volume":"10","author":"J Adamski","year":"2010","unstructured":"Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153. doi: 10.1186\/1472-6963-10-153 .","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"44_CR3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004479-200404000-00009","volume":"27","author":"M Duerden","year":"2004","unstructured":"Duerden M, Gogna N, Godman B, Eden K, Mallinson M, Sullivan N. Current National Initiatives and Policies to Control Drug Costs in Europe: UK Perspective. J Ambul Care Manag. 2004;27(2):132\u20138.","journal-title":"J Ambul Care Manag"},{"issue":"3","key":"44_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/annonc\/mdn603","volume":"20","author":"CJ McCabe","year":"2009","unstructured":"McCabe CJ, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, et al. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol. 2009;20(3):403\u201312. doi: 10.1093\/annonc\/mdn603 .","journal-title":"Ann Oncol"},{"issue":"3","key":"44_CR5","doi-asserted-by":"crossref","first-page":"A95","DOI":"10.1016\/S1098-3015(10)72454-2","volume":"13","author":"A Cano-Chancel","year":"2010","unstructured":"Cano-Chancel A, Long M, Sparrowhawk K. Risk sharing: what\u2019s at risk and what\u2019s being shared. Value Health. 2010;13(3):A95.","journal-title":"Value Health"},{"issue":"7472","key":"44_CR6","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1136\/bmj.329.7472.972","volume":"329","author":"RS Taylor","year":"2004","unstructured":"Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 2004;329(7472):972\u20135.","journal-title":"BMJ"},{"issue":"5","key":"44_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","volume":"16","author":"LP Garrison Jr","year":"2013","unstructured":"Garrison LP Jr, Towse A, Briggs A, De Pouvourville G, Grueger J, Mohr PE, et al. Performance-based risk-sharing arrangements\u2014good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703\u201319. doi: 10.1016\/j.jval.2013.04.011 .","journal-title":"Value Health"},{"issue":"7","key":"44_CR8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00019053-200826070-00002","volume":"26","author":"JP Cook","year":"2008","unstructured":"Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2008;26(7):551\u20136.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"44_CR9","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1093\/annonc\/mdq097","volume":"21","author":"P Russo","year":"2010","unstructured":"Russo P, Mennini FS, Siviero PD, Rasi G. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol. 2010;21(10):2081\u20137. doi: 10.1093\/annonc\/mdq097 .","journal-title":"Ann Oncol"},{"issue":"3","key":"44_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-006-0386-6","volume":"7","author":"G Pouvourville De","year":"2006","unstructured":"De Pouvourville G. Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ. 2006;7(3):155\u20137. doi: 10.1007\/s10198-006-0386-6 .","journal-title":"Eur J Health Econ"},{"issue":"2","key":"44_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11530850-000000000-00000","volume":"28","author":"CJ McCabe","year":"2010","unstructured":"McCabe CJ, Stafinski T, Edlin R, Menon D, Behalf Banff AEDS. Access with evidence development schemes a framework for description and evaluation. Pharmacoeconomics. 2010;28(2):143\u201352.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"44_CR12","doi-asserted-by":"crossref","first-page":"A359","DOI":"10.1016\/j.jval.2011.08.696","volume":"14","author":"JJ Carlson","year":"2011","unstructured":"Carlson JJ, Gries K, Sullivan SD, Garrison L. Current status and trends in performance-based schemes between health care payers and manufacturers. Value Health. 2011;14(7):A359\u201360.","journal-title":"Value Health"},{"issue":"1","key":"44_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S0266462310001297","volume":"27","author":"M Klemp","year":"2011","unstructured":"Klemp M, Fronsdal KB, Facey K. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011;27(1):77\u201383.","journal-title":"Int J Technol Assess Health Care"},{"issue":"12","key":"44_CR14","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1377\/hlthaff.2010.1147","volume":"30","author":"PJ Neumann","year":"2011","unstructured":"Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff. 2011;30(12):2329\u201337. doi: 10.1377\/hlthaff.2010.1147 .","journal-title":"Health Aff"},{"key":"44_CR15","unstructured":"Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment and health outcomes: a systematic review and taxonomy of performance-based health outcomes agreements between health care payers and manufacturers. Blackwell Publishing Inc.; 2009. http:\/\/www.valueinhealthjournal.com\/article\/S1098-3015(10)73513-0\/abstract . Accessed 13 April 2015."},{"issue":"7","key":"44_CR16","doi-asserted-by":"crossref","first-page":"A322","DOI":"10.1016\/j.jval.2012.08.732","volume":"15","author":"G Ando","year":"2012","unstructured":"Ando G, Izmirlieva M, Honore AC. Global pharmaceutical risk-sharing agreement trends in 2011 and 2012: slowing down? Value Health. 2012;15(7):A322\u20133.","journal-title":"Value Health"},{"key":"44_CR17","unstructured":"Spoors J, Brown C, Johnson N, Rietveld A. Patient access schemes in the new NHS. London: RJW and Partners; 2012. http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=70915993 . Accessed 13 April 2015."},{"issue":"3","key":"44_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40258-014-0093-x","volume":"12","author":"JJ Carlson","year":"2014","unstructured":"Carlson JJ, Gries KS, Yeung K, Sullivan SD, Garrison LP Jr. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy. 2014;12(3):231\u20138.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"44_CR19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2014.09.007","volume":"18","author":"A Navarria","year":"2014","unstructured":"Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, et al. Do the current performance-based schemes in Italy really work? \u201cSuccess fee\u201d: a novel measure for cost-containment of drug expenditure. Value Health. 2014;18(1):131\u20136.","journal-title":"Value Health"},{"issue":"7","key":"44_CR20","doi-asserted-by":"crossref","first-page":"A391","DOI":"10.1016\/j.jval.2013.08.397","volume":"16","author":"T Morel","year":"2013","unstructured":"Morel T, Arickx F, Befrits G, Siviero PD, Van Der Meijden CMJ, Xoxi E, et al. Managed entry agreements and orphan drugs: a European comparative study (2006\u20132012). Value Health. 2013;16(7):A391.","journal-title":"Value Health"},{"key":"44_CR21","first-page":"154","volume-title":"Managed entry agreements for pharmaceuticals: the European experience","author":"A Ferrario","year":"2013","unstructured":"Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. London: London School of Economics and Political Science; 2013. p. 154."},{"issue":"2","key":"44_CR22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/11314080-000000000-00000","volume":"28","author":"A Towse","year":"2010","unstructured":"Towse A, Garrison LP Jr. Can\u2019t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 2010;28(2):93\u2013102.","journal-title":"Pharmacoeconomics"},{"key":"44_CR23","volume-title":"Research design: qualitative, quantitative, and mixed methods approaches","author":"JW Creswell","year":"2013","unstructured":"Creswell JW. Research design: qualitative, quantitative, and mixed methods approaches. Thousand Oaks: SAGE Publications; 2013."},{"key":"44_CR24","doi-asserted-by":"publisher","DOI":"10.17169\/fqs-7.1.75","author":"F Kohlbacher","year":"2006","unstructured":"Kohlbacher F. The Use of qualitative content analysis in case study research. Forum Qual Soc Res. 2006. doi: 10.17169\/fqs-7.1.75 .","journal-title":"Forum Qual Soc Res"},{"key":"44_CR25","unstructured":"Mayring P. Qualitative content analysis. Forum Qual Soc Res. 2000;1(2):3\u20134."},{"issue":"7391","key":"44_CR26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/bmj.326.7391.707","volume":"326","author":"S Chapman","year":"2003","unstructured":"Chapman S, Reeve E, Rajaratnam G, Neary R. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. BMJ. 2003;326(7391):707\u20139.","journal-title":"BMJ"},{"issue":"7321","key":"44_CR27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/bmj.323.7321.1087","volume":"323","author":"S Mayor","year":"2001","unstructured":"Mayor S. Health department to fund interferon beta despite institute\u2019s ruling. BMJ. 2001;323(7321):1087.","journal-title":"BMJ"},{"issue":"7388","key":"44_CR28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/bmj.326.7388.522","volume":"326","author":"J Chilcott","year":"2003","unstructured":"Chilcott J, Miller DH, McCabe C, Tappenden P, Hagan A, Cooper NJ, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: Evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326(7388):522.","journal-title":"BMJ"},{"issue":"7385","key":"44_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/bmj.326.7385.388","volume":"326","author":"CLM Sudlow","year":"2003","unstructured":"Sudlow CLM, Counsell CE. Problems with UK government\u2019s risk sharing scheme for assessing drugs for multiple sclerosis. BMJ. 2003;326(7385):388\u201392. doi: 10.1136\/bmj.326.7385.388 .","journal-title":"BMJ"},{"issue":"6","key":"44_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/hec.1249","volume":"16","author":"K Claxton","year":"2007","unstructured":"Claxton K. OFT, VBP: QED? Health Econ. 2007;16(6):545\u201358. doi: 10.1002\/hec.1249 .","journal-title":"Health Econ"},{"issue":"7","key":"44_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/hec.1263","volume":"16","author":"A Towse","year":"2007","unstructured":"Towse A. If it ain\u2019t broke, don\u2019t price fix it: the OFT and the PPRS. Health Econ. 2007;16(7):653\u201365. doi: 10.1002\/hec.1263 .","journal-title":"Health Econ"},{"issue":"10","key":"44_CR32","doi-asserted-by":"crossref","first-page":"9981","DOI":"10.1002\/hec.1300","volume":"16","author":"S Thornton","year":"2007","unstructured":"Thornton S. Drug price reform in the UK: debunking the myths. Health Econ. 2007;16(10):9981\u201392.","journal-title":"Health Econ"},{"key":"44_CR33","doi-asserted-by":"crossref","unstructured":"Carroll SM, Wasiak R. Patient access schemes-the use of risk-sharing in the UK. Value in Health, 2009; 12(7):A286\u2013A287. http:\/\/www.valueinhealthjournal.com\/article\/S1098-3015(10)74405-3\/pdf . Accessed 13 April 2015.","DOI":"10.1016\/S1098-3015(10)74405-3"},{"key":"44_CR34","unstructured":"V\u00eddc\u00e1rcel BGL. About Drugs: Therapeutic value, social value and market value Basic & Clinical Pharmacology & Toxicology. 2011; 109:2. https:\/\/insights.ovid.com\/basic-clinical-pharmacologytoxicology\/phtox\/2011\/10\/003\/drugs-therapeutic-value-social-market\/21\/00152251 . Accessed 13 April 2015."},{"key":"44_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1750-1172-8-198","volume":"8","author":"T Morel","year":"2013","unstructured":"Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis. 2013;8:198. doi: 10.1186\/1750-1172-8-198 .","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"44_CR36","doi-asserted-by":"crossref","first-page":"A261","DOI":"10.1016\/j.jval.2013.03.1337","volume":"16","author":"Y Hao","year":"2013","unstructured":"Hao Y. Health technology assessment and value-based pricing in Germany, the United Kingdom and France: recent developments and implications. Value Health. 2013;16(3):A261.","journal-title":"Value Health"},{"key":"44_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1472-6963-13-88","volume":"13","author":"D Bishop","year":"2013","unstructured":"Bishop D, Lexchin J. Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews. BMC Health Serv Res. 2013;13:88. doi: 10.1186\/1472-6963-13-88 .","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"44_CR38","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jval.2014.01.010","volume":"17","author":"R Edlin","year":"2014","unstructured":"Edlin R, Hall P, Wallner K, McCabe C. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? Value Health. 2014;17(4):438\u201344. doi: 10.1016\/j.jval.2014.01.010 .","journal-title":"Value Health"},{"issue":"7","key":"44_CR39","doi-asserted-by":"crossref","first-page":"A243","DOI":"10.1016\/S1098-3015(10)74187-5","volume":"12","author":"F Lucas","year":"2009","unstructured":"Lucas F, Easley C, Jackson G. The usefulness and challenges of patient acess (risk sharing) schemes in the UK. Value Health. 2009;12(7):A243.","journal-title":"Value Health"},{"issue":"7","key":"44_CR40","doi-asserted-by":"crossref","first-page":"A436","DOI":"10.1016\/j.jval.2012.08.2188","volume":"15","author":"A Chawla","year":"2012","unstructured":"Chawla A, Oza A, Nellesen D, Brown J, Liepa AM, Price G, et al. Review of National Institute for Health And Clinical Excellence (NICE) recommendations for anti-cancer agents across multiple drug-indication combinations. Value Health. 2012;15(7):A436.","journal-title":"Value Health"},{"key":"44_CR41","doi-asserted-by":"crossref","unstructured":"Cheema PK, Gavura S, Godman B, Yeung L, Trudeau ME. Global variations in reimbursement of new cancer therapeutics: Improving access through risk-sharing agreements. J Clin Oncol. 2010; 28(15_suppl):6050. http:\/\/ascopubs.org\/doi\/abs\/10.1200\/jco.2010.28.15_suppl.6050 . Accessed 13 April 2015.","DOI":"10.1200\/jco.2010.28.15_suppl.6050"},{"issue":"3","key":"44_CR42","doi-asserted-by":"crossref","first-page":"A96","DOI":"10.1016\/S1098-3015(10)72459-1","volume":"13","author":"S Costello","year":"2010","unstructured":"Costello S, Haynes S, Kusel J. Innovative pricing agreements in UK NICE submissions. Value Health. 2010;13(3):A96.","journal-title":"Value Health"},{"issue":"7","key":"44_CR43","doi-asserted-by":"crossref","first-page":"A481","DOI":"10.1016\/j.jval.2013.08.917","volume":"16","author":"R Barber","year":"2013","unstructured":"Barber R, Steeves S, Kusel J, Wilson T, Hamerslag L. How does the uncertainty around the expected ICER affect NICE decisions? Value Health. 2013;16(7):A481.","journal-title":"Value Health"},{"issue":"7","key":"44_CR44","doi-asserted-by":"crossref","first-page":"A472","DOI":"10.1016\/j.jval.2013.08.866","volume":"16","author":"T Nijhuis","year":"2013","unstructured":"Nijhuis T, Haigh J, Van Engen A. Confidential patient access schemes in the United Kingdom\u2014do they affect prices in other markets? Value Health. 2013;16(7):A472\u20133.","journal-title":"Value Health"},{"issue":"7","key":"44_CR45","doi-asserted-by":"crossref","first-page":"A245","DOI":"10.1016\/S1098-3015(11)71874-5","volume":"13","author":"L Banerji","year":"2010","unstructured":"Banerji L, Das S. Retrospective analysis of technology appraisals conducted by UK\u2019s national institute for health and clinical excellence (NICE) in several cancer indications: higher evidence barriers for targeted therapies? Value Health. 2010;13(7):A245\u20136.","journal-title":"Value Health"},{"issue":"6","key":"44_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.gaceta.2010.07.011","volume":"24","author":"J Espin","year":"2010","unstructured":"Espin J, Oliva J, Manuel Rodriguez-Barrios J. Innovative patient access schemes for the adoption of new technology: risk-sharing agreements. Gac Sanit. 2010;24(6):491\u20137. doi: 10.1016\/j.gaceta.2010.07.011 .","journal-title":"Gac Sanit"},{"issue":"2","key":"44_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1215\/03616878-2007-054","volume":"33","author":"JP Cohen","year":"2008","unstructured":"Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law. 2008;33(2):225\u201347. doi: 10.1215\/03616878-2007-054 .","journal-title":"J Health Polit Policy Law"},{"issue":"11","key":"44_CR48","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/nbt1110-1160","volume":"28","author":"J Cohen","year":"2010","unstructured":"Cohen J, Looney W. What is the value of oncology medicines? Nat Biotechnol. 2010;28(11):1160\u20133. doi: 10.1038\/nbt1110-1160 .","journal-title":"Nat Biotechnol"},{"issue":"3","key":"44_CR49","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1365-2125.2010.03740.x","volume":"70","author":"A Towse","year":"2010","unstructured":"Towse A. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Br J Clin Pharmacol. 2010;70(3):360\u20136. doi: 10.1111\/j.1365-2125.2010.03740.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"44_CR50","doi-asserted-by":"crossref","first-page":"A568","DOI":"10.1016\/j.jval.2015.09.1868","volume":"18","author":"L Pritchett","year":"2015","unstructured":"Pritchett L, Wiesinger A, Faria-Billinton E, Brown A, Murray G, Stoor L, et al. A review of guidelines and approaches to performance-based risk-sharing agreements across the UK, Italy and the Netherlands. Value Health. 2015;18(7):A568.","journal-title":"Value Health"},{"issue":"3","key":"44_CR51","doi-asserted-by":"crossref","first-page":"A9","DOI":"10.1016\/j.jval.2015.03.059","volume":"18","author":"V Briceno","year":"2015","unstructured":"Briceno V, Seoane-Vazquez E. Analysis of nice drug technology appraisals (2001\u2013September 2014). Value Health. 2015;18(3):A9.","journal-title":"Value Health"},{"issue":"7","key":"44_CR52","doi-asserted-by":"crossref","first-page":"A568","DOI":"10.1016\/j.jval.2015.09.1869","volume":"18","author":"S Walzer","year":"2015","unstructured":"Walzer S, Droeschel D, Shannon R. Which risk share agreements are available and are those applied in global reimbursement decisions? Value Health. 2015;18(7):A568.","journal-title":"Value Health"},{"issue":"7","key":"44_CR53","doi-asserted-by":"crossref","first-page":"A765","DOI":"10.1016\/j.jval.2015.09.2512","volume":"18","author":"M Sumra","year":"2015","unstructured":"Sumra M, Walters E. A long term analysis of the clinical and cost effectiveness of glatiramer acetate from the UK multiple sclerosis risk sharing scheme. Value Health. 2015;18(7):A765\u20136.","journal-title":"Value Health"},{"key":"44_CR54","first-page":"800","volume":"1","author":"G Giovannoni","year":"2015","unstructured":"Giovannoni G, Brex P, Sumra M, Walters E, Schmierer K. Glatiramer acetate slows disability progression: results from a 6-year analysis of the UK Risk Sharing Scheme. Mult Scler. 2015;1:800\u20131.","journal-title":"Mult Scler"},{"issue":"3","key":"44_CR55","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/s1744133111000016","volume":"6","author":"F Antonanzas","year":"2011","unstructured":"Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law. 2011;6(3):391\u2013403. doi: 10.1017\/s1744133111000016 .","journal-title":"Health Econ Policy Law"},{"issue":"7","key":"44_CR56","doi-asserted-by":"crossref","first-page":"A552","DOI":"10.1016\/j.jval.2015.09.1775","volume":"18","author":"A Tettamanti","year":"2015","unstructured":"Tettamanti A, Urbinati D, Noble M. Market access entry agreements in the Italian market between January 2006 and April 2015. Value Health. 2015;18(7):A552.","journal-title":"Value Health"},{"issue":"4","key":"44_CR57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1017\/S0266462315000446","volume":"31","author":"S Montilla","year":"2015","unstructured":"Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. Monitoring registries at Italian medicines agency: fostering access, guaranteeing sustainability. Int J Technol Assess Health Care. 2015;31(4):210\u20133. doi: 10.1017\/S0266462315000446 .","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"44_CR58","doi-asserted-by":"crossref","first-page":"A505","DOI":"10.1016\/j.jval.2015.09.1440","volume":"18","author":"A Fasci","year":"2015","unstructured":"Fasci A, Ferrario M, Ravasio R, Ena R, Angelini S, Giuliani G. Conditional agreements for innovative therapies in Italy: the case of pirfenidone. Value Health. 2015;18(7):A505.","journal-title":"Value Health"},{"issue":"1","key":"44_CR59","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1586\/14737167.2014.898566","volume":"15","author":"K Kolasa","year":"2015","unstructured":"Kolasa K, Kalo Z, Hornby E. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices. Expert Rev Pharmacoeconomics Outcomes Res. 2015;15(1):145\u201355. doi: 10.1586\/14737167.2014.898566 .","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"7","key":"44_CR60","doi-asserted-by":"crossref","first-page":"A567","DOI":"10.1016\/j.jval.2015.09.1862","volume":"18","author":"J Zizalova","year":"2015","unstructured":"Zizalova J, Rrahmaniova D, Svorcikova J, Vrubel F. The relation between real costs of drugs temporarily reimbursed in mode of coverage with evidence development and budget impact analysis submitted as a mandatory requirement of the application. Value Health. 2015;18(7):A567.","journal-title":"Value Health"},{"issue":"7","key":"44_CR61","doi-asserted-by":"crossref","first-page":"A689","DOI":"10.1016\/j.jval.2015.09.2554","volume":"18","author":"T Kocsis","year":"2015","unstructured":"Kocsis T, Papp E, Nemeth B, Juhasz J. The cost of treatment of the new antiviral therapies against the hepatitis C virus. Value Health. 2015;18(7):A689.","journal-title":"Value Health"},{"issue":"7","key":"44_CR62","doi-asserted-by":"crossref","first-page":"A571","DOI":"10.1016\/j.jval.2015.09.1887","volume":"18","author":"M Petrov","year":"2015","unstructured":"Petrov M, Hubenov P. Introduction of formal risk sharing agreements (RSA): a promising solution for sustainable and predictable pharmaceutical expenditures in Bulgaria. Value Health. 2015;18(7):A571\u20132.","journal-title":"Value Health"},{"issue":"7","key":"44_CR63","doi-asserted-by":"crossref","first-page":"A730","DOI":"10.1016\/j.jval.2015.09.2782","volume":"18","author":"S Focsa","year":"2015","unstructured":"Focsa S. Can advances in health monitors lead to health being looked at as a commodity? Value Health. 2015;18(7):A730.","journal-title":"Value Health"},{"issue":"3","key":"44_CR64","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/ecc.12240","volume":"24","author":"G Dranitsaris","year":"2015","unstructured":"Dranitsaris G, Dorward K, Owens RC, Schipper H. What is a new drug worth? An innovative model for performance-based pricing. Eur J Cancer Care. 2015;24(3):313\u201320. doi: 10.1111\/ecc.12240 .","journal-title":"Eur J Cancer Care"},{"issue":"2","key":"44_CR65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1356389015577464","volume":"21","author":"F Battye","year":"2015","unstructured":"Battye F. Payment by results in the UK: progress to date and future directions for evaluation. Evaluation. 2015;21(2):189\u2013203. doi: 10.1177\/1356389015577464 .","journal-title":"Evaluation"},{"issue":"9","key":"44_CR66","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40273-015-0293-8","volume":"33","author":"B Parkinson","year":"2015","unstructured":"Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics. 2015;33(9):905\u201324. doi: 10.1007\/s40273-015-0293-8 .","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"44_CR67","doi-asserted-by":"crossref","first-page":"A550","DOI":"10.1016\/j.jval.2015.09.1766","volume":"18","author":"J Mycka","year":"2015","unstructured":"Mycka J, Dellamano R, Lobb W, Dellamano L, Dalal N. Orphan drugs assessment in Germany: a comparison with other international HTA agencies. Value Health. 2015;18(7):A550\u20131.","journal-title":"Value Health"},{"issue":"8","key":"44_CR68","doi-asserted-by":"publisher","first-page":"683","DOI":"10.18553\/jmcp.2009.15.8.683","volume":"15","author":"JJ Carlson","year":"2009","unstructured":"Carlson JJ, Garrison LP Jr, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J Manag Care Pharm. 2009;15(8):683\u20137. doi: 10.18553\/jmcp.2009.15.8.683 .","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"44_CR69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1107\/0261018304039679","volume":"24","author":"I Crinson","year":"2004","unstructured":"Crinson I. The politics of regulation within the \u2018modernized\u2019 NHS: the case of beta interferon and the \u2018cost-effective\u2019 treatment of multiple sclerosis. Crit Soc Policy. 2004;24(1):30\u201349. doi: 10.1107\/0261018304039679 .","journal-title":"Crit Soc Policy"},{"issue":"1","key":"44_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00023210-200418010-00001","volume":"18","author":"T Walley","year":"2004","unstructured":"Walley T. Neuropsychotherapeutics in the UK\u2014what has been the impact of NICE on prescribing? CNS Drugs. 2004;18(1):1\u201312. doi: 10.2165\/00023210-200418010-00001 .","journal-title":"CNS Drugs"},{"issue":"3","key":"44_CR71","doi-asserted-by":"crossref","first-page":"A100","DOI":"10.1016\/j.jval.2015.03.586","volume":"18","author":"T Nazareth","year":"2015","unstructured":"Nazareth T, Ko JJ, Frois C, Carpenter S, Demean S, Wu EQ, et al. Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in The US and EU-5: payer and manufacturer experience and outlook. Value Health. 2015;18(3):A100.","journal-title":"Value Health"},{"issue":"1","key":"44_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40258-015-0182-5","volume":"14","author":"U Persson","year":"2016","unstructured":"Persson U, Jonsson B. The end of the international reference pricing system? Appl Health Econ Health Policy. 2016;14(1):1\u20138. doi: 10.1007\/s40258-015-0182-5 .","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"44_CR73","doi-asserted-by":"crossref","first-page":"A241","DOI":"10.1016\/S1098-3015(11)71855-1","volume":"13","author":"G Ando","year":"2010","unstructured":"Ando G, Kowal S, Reinaud F. Payer roadblocks to risk-sharing agreements around the world: where, when and how? Value Health. 2010;13(7):A241.","journal-title":"Value Health"},{"issue":"4","key":"44_CR74","doi-asserted-by":"crossref","first-page":"A164","DOI":"10.1016\/j.jval.2012.03.888","volume":"15","author":"O Ethgen","year":"2012","unstructured":"Ethgen O. One day money will only be spent on effective drugs. From payers\u2019 aspirations to performance-based risk-sharing operations. Value Health. 2012;15(4):A164.","journal-title":"Value Health"},{"key":"44_CR75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.socscimed.2014.11.003","volume":"124","author":"A Ferrario","year":"2015","unstructured":"Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39\u201347. doi: 10.1016\/j.socscimed.2014.11.003 .","journal-title":"Soc Sci Med"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-017-0044-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-017-0044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-017-0044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T15:38:49Z","timestamp":1569857929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-017-0044-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1007\/s41669-017-0044-1","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]}}}